This repurposed antidepressant was recently approved in ADHD, but how does it compare with other treatments?

A simple intervention improves depression in patients with hearing loss.

Choosing an antipsychotic in bipolar disorder just got more complicated. This series of industry-sponsored trials reveals that their anti-manic activity may not be a class effect.

Omega-3s are helpful for negative symptoms in schizophrenia, and this study suggests they may have metabolic benefits as well.

Randomized controlled trials have not been kind to commercial pharmacogenetic panels, but will Genecept’s fate be any different?

Medications don’t have a good track record in PTSD, particularly in combat related trauma. Here we review two controlled trials where an old standby (mirtazapine) and a hopeful contender (riluzole) come up short.

This first-of-its-kind study looked at lightbox in PTSD with a randomized, placebo-controlled design.

Electroconvulsive therapy (ECT) remains both controversial and difficult to obtain for children and adolescents. Yet when our young patients have truly severe and life-threatening neuropsychiatric conditions, when medication is not going to cut it, we look to ECT for possible help. This research review offers guidance for use of ECT.

Should you stop the old antipsychotic and start the new? Or gradually cross-taper them? This new meta-analysis compared three titration strategies to find the best way to switch from one antipsychotic to another in schizophrenia.